Compare HP Inc (HPQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs State Street SPDR S&P Biotech ETF — how do they compare? HP Inc trades at $24.63 (market cap $22.15B), while State Street SPDR S&P Biotech ETF trades at $154.06. The key difference: HP Inc pays a 4.95% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, HP Inc nearer its low. Which is the better fit depends on your goals.
| HPQ | XBI | |
|---|---|---|
Market Cap | $22.15B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $29.35 | $164.28 |
52-Week Low | $18.20 | $85.16 |
Enterprise Value | $29.31B | — |
Dividend Yield | 4.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $24.395, down 1.79% on the day, with a bullish technical setup showing strong moving average signals. The stock offers attractive valuation metrics including a P/E of 9.2 and P/S of 0.41, with consistent earnings beats in recent quarters. Recent developments include strategic partnerships with OpenAI and Ferrari, positioning the company for AI PC growth. Cash flow trends show improvement with 2025 net cash flow of $460 million, though revenue has declined from 2022's $63B to $55.3B in 2025.
HPQ presents a value opportunity with strong dividend yield and improving cash flows, but faces headwinds from PC market volatility and competitive pressures. Analyst sentiment is mixed with 29% buy ratings versus 55% hold, suggesting cautious optimism. The stock's near-term performance will depend on AI PC adoption and execution of new strategic partnerships.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
